NASDAQ$CRNX
Crinetics Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023.
Crinetics Pharmaceuticals reported revenue of $1 million and a net loss of $51.0 million for the second quarter of 2023. The PATHFNDR program for acromegaly continues to progress, with topline results from the Phase 3 PATHFNDR-1 study expected in September and enrollment completed in the Phase 3 PATHFNDR-2 study. The company has suspended development of CRN04777.
- Topline data from paltusotine’s Phase 3 PATHFNDR-1 study expected in September 2023.
- Completed enrollment in paltusotine’s Phase 3 PATHFNDR-2 study with topline data expected in the first quarter of 2024.
- Paltusotine NDA submission anticipated in 2024.
- Development of CRN04777 suspended.
Headline financials
Revenue & EPS history
Crinetics · Revenue · Quarterly
$988K
Revenue by segment
Crinetics · $1.1M total across 1 segment · Q4 2021
- Collaboration and license$1.1M—100.0%
Forward guidance
Crinetics expects topline data from the PATHFNDR-1 study in September 2023 and from the PATHFNDR-2 study in Q1 2024. They anticipate submitting an NDA for paltusotine in 2024.
Tailwinds
- Topline data from paltusotine’s Phase 3 PATHFNDR-1 study expected in September 2023.
- Enrollment completed in paltusotine’s Phase 3 PATHFNDR-2 study.
- Paltusotine NDA submission anticipated in 2024.
- Phase 2 open-label study of paltusotine in carcinoid syndrome ongoing with preliminary data anticipated in the fourth quarter of 2023.
- CRN04894 studies in Cushing’s disease and congenital adrenal hyperplasia are ongoing with data expected in 2024.
Headwinds
- Development of CRN04777 suspended.
- Net loss for the three months ended June 30, 2023, was $51.0 million.
- The company may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights.
- The COVID-19 pandemic and other geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends.
- Unexpected adverse side effects or inadequate efficacy of the company’s product candidates that may limit their development, regulatory approval and/or commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.1%
Avg return
Earnings day
+1.4%
Avg return
5 days after
-1.0%
Avg return
30 days after
45%
14 / 31 earnings
Positive
+14.8%
Q2 2020
Best reaction
-13.0%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -11.5% | -21.1% | |
| Q4 2025 | -6.1% | -9.7% | -23.0% | |
| Q3 2025 | -8.0% | -1.5% | +7.3% | |
| Q1 2025 | -6.2% | -4.3% | +0.9% | |
| Q4 2024 | +7.7% | +2.2% | +4.6% | |
| Q3 2024 | -1.8% | -8.8% | -7.3% | |
| Q2 2024 | -1.4% | +4.2% | +4.3% | |
| Q1 2024 | -5.7% | -3.0% | -12.1% | |
| Q4 2023 | +1.2% | +7.5% | +15.7% | |
| Q3 2023 | -6.7% | -11.7% | +9.8% | |
| Q2 2023 | -7.3% | -8.3% | -10.2% | |
| Q1 2023 | +3.6% | +9.4% | +2.0% | |
| Q4 2022 | +2.2% | -0.3% | -17.6% | |
| Q3 2022 | -0.8% | -3.0% | -11.4% | |
| Q2 2022 | +8.6% | +4.3% | +2.1% | |
| Q1 2022 | +11.2% | +26.2% | +10.3% | |
| Q4 2021 | +11.6% | +25.3% | +3.3% | |
| Q3 2021 | +0.7% | -0.8% | -10.7% | |
| Q2 2021 | +13.3% | +31.9% | +40.8% | |
| Q1 2021 | -0.7% | -3.2% | -0.8% | |
| Q4 2020 | -0.7% | +4.0% | +15.4% | |
| Q3 2020 | -7.8% | -1.2% | -2.6% | |
| Q2 2020 | +14.8% | +3.4% | -5.3% | |
| Q1 2020 | +14.3% | +14.8% | -5.8% | |
| Q4 2019 | -13.0% | -33.2% | -33.1% | |
| Q3 2019 | -0.4% | -3.6% | +13.3% | |
| Q2 2019 | -4.5% | -0.6% | -8.1% | |
| Q1 2019 | -2.3% | +0.8% | -12.8% | |
| Q4 2018 | +8.1% | +8.1% | -0.3% | |
| Q3 2018 | +8.8% | +8.5% | +27.9% | |
| Q2 2018 | -2.9% | -2.5% | -7.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro